Shotgun Metagenomics Clinical Reporting Market Report 2026

Shotgun Metagenomics Clinical Reporting Market Report 2026 Market Overview

• Shotgun Metagenomics Clinical Reporting Market Report 2026 market size has reached to $1.58 billion in 2025 • Expected to grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 16.7% • Growth Driver: Rising Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Increasing Demand For Rapid Pathogen Identification And Precision Infectious Disease Diagnostics Solutions • Market Trend: Precision Respiratory Infection Testing Strengthening Clinical Metagenomics Applications • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Shotgun Metagenomics Clinical Reporting Market?

The shotgun metagenomics clinical reporting refers to a diagnostic approach that uses next-generation sequencing to analyze all genetic material present in a clinical sample. It enables unbiased detection of bacteria, viruses, fungi, and parasites without targeting specific organisms. The sequencing data is interpreted using bioinformatics tools to identify pathogens and antimicrobial resistance markers. The main product types of shotgun metagenomics clinical reporting include software and services. Software refers to digital platforms designed to analyze complex metagenomic sequencing data and generate clinical reports for diagnostic and research use. These solutions analyze sample types including blood samples, stool samples, respiratory samples, cerebrospinal fluid samples, tissue biopsy samples, urine samples, and other body fluid samples and utilize sequencing technologies such as short read sequencing, long read sequencing, and hybrid sequencing. The key applications of infectious disease diagnostics, oncology, microbiome analysis, antimicrobial resistance, and others, while the end-user types hospitals and clinics, diagnostic laboratories, research institutes, and others.

What Is The Shotgun Metagenomics Clinical Reporting Market Growth Forecast?

The shotgun metagenomics clinical reporting market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to expansion of precision medicine and personalized diagnostics adoption, increasing integration of AI in genomic data interpretation, growth in decentralized and point-of-care sequencing systems, rising demand for rapid pathogen detection in critical care settings, expansion of cloud-based bioinformatics platforms for clinical workflows. Major trends in the forecast period include ai-driven pathogen detection and automated clinical interpretation systems, cloud-based genomic data sharing platforms for real-time diagnostics, ultra-rapid sequencing workflows for point-of-care infectious disease detection, integrated antimicrobial resistance prediction using genomic analytics, decentralized sequencing systems for hospital-based rapid metagenomic testing.

What Is The Driver Of The Shotgun Metagenomics Clinical Reporting Market?

The rising prevalence of infectious diseases is expected to propel the growth of the shotgun metagenomics clinical reporting market going forward. Infectious diseases are disorders caused by pathogenic microorganisms, including bacteria, viruses, fungi, and parasites, that can spread between individuals, animals, or environmental sources. The prevalence of infectious diseases is increasing due to the growing frequency of disease outbreaks associated with greater global connectivity and population movement. Shotgun metagenomics clinical reporting helps in infectious diseases by enabling rapid and comprehensive identification of pathogens, antimicrobial resistance markers, and co-infections from clinical samples to support accurate diagnosis and targeted treatment. For instance, in October 2024, according to the World Health Organization, a Switzerland-based public health organization, an estimated 8.2 million people were newly diagnosed with tuberculosis in 2023, compared to 7.5 million people in 2022, representing an increase of approximately 9.3%. Therefore, the rising prevalence of infectious diseases is driving the growth of the shotgun metagenomics clinical reporting industry.

Key Players In The Global Shotgun Metagenomics Clinical Reporting Market

Major companies operating in the shotgun metagenomics clinical reporting market report are BaseClear B.V., BGI Genomics Co. Ltd., BugSeq Bioinformatics Inc., CD Genomics Inc., Cmbio, Eurofins Scientific, Genome Detective, Illumina Inc., Karius Inc., Macrogen Inc., Microba Life Sciences Limited, Novogene Co. Ltd., Nucleome Informatics Private Limited, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Psomagen Inc., QIAGEN N.V., Revvity Inc., Strand Life Sciences Private Limited, Synnovis Group LLP, Takara Bio Inc., Thermo Fisher Scientific Inc., Yaazh Xenomics Private Limited, Zymo Research Corporation

Global Shotgun Metagenomics Clinical Reporting Market Trends and Insights

Major companies operating in the shotgun metagenomics clinical reporting market are focusing on developing advanced solutions, such as respiratory-focused genomic panels that analyze microbial cell-free DNA from targeted clinical fluids to improve standard care for vulnerable patient populations. Respiratory-focused genomic panels represent a targeted application of metagenomic sequencing designed to isolate and sequence fragmented pathogen DNA directly from complex, matrix-specific bodily fluids like lung washes to deliver fast, culture-independent diagnosis of complicated respiratory tract infections. For instance, in April 2025, Karius Inc., a US-based life sciences company, launched Karius Focus BAL, a comprehensive metagenomic sequencing test that utilizes bronchoalveolar lavage fluid to analyze microbial cell-free DNA. The diagnostic application analyzes fluid samples directly to detect over 500 pathogens, delivers processed diagnostic results within one calendar day of sample receipt, and identifies 50% more causes of infectious pneumonia compared to standard conventional testing methodologies.

What Are Latest Mergers And Acquisitions In The Shotgun Metagenomics Clinical Reporting Market?

In April 2026, Karius Inc., a US-based infectious disease diagnostics company, partnered with Mayo Clinic Laboratories to expand access to advanced metagenomic infectious disease testing. The partnership aims to make Karius’s Karius Spectrum and Karius Focus | BAL tests available for ordering through Mayo Clinic Laboratories, improving access to comprehensive pathogen detection and clinical diagnostic reporting. Mayo Clinic Laboratories is a US-based clinical laboratory services provider specializing in advanced diagnostic testing and laboratory medicine.

What Defines the Shotgun Metagenomics Clinical Reporting Market?

The shotgun metagenomics clinical reporting market consists of revenues earned by entities by providing services such as end-to-end genomic diagnostic services, sample processing, next-generation sequencing, bioinformatics analysis, pathogen identification, antimicrobial resistance profiling, and clinical interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. The shotgun metagenomics clinical reporting market also includes sales of benchtop dna sequencers, high-throughput sequencing systems, automated nucleic acid extraction systems, sample preparation workstations, and library preparation instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Shotgun Metagenomics Clinical Reporting Market Report 2026?

The shotgun metagenomics clinical reporting market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the shotgun metagenomics clinical reporting industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.